argenx SE Stock News

August 31 , 2022 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, tod

Does argenex SE (ARGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does argenex SE (ARGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.

Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.

Immunovant (IMVT) remains focused on developing its lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. The lack of other pipeline candidates remains a concern.

SSB, XOM and ARGX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 3, 2022.

Here is how McKesson (MCK) and argenex SE (ARGX) have performed compared to their sector so far this year.

argenx reported another strong quarter with $74.9 million in Vyvgart net sales. The company added 1,000 new patients in Q2, up from 400 in Q1.

HC Wainwright is bullish on Argenx SE's (NASDAQ: ARGX) Vyvgart (efgartigimod). "We think it's becoming obvious that Vyvgart is going to be a blockbuster sooner rather than later, as it establishes

Upgrades For The Carlyle Group Inc (NASDAQ:CG), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. Carlyle Group earned $1.17 in the second quarter, compared to $0.88 in the ye

ARGX earnings call for the period ending June 30, 2022.

argenx SE (NASDAQ:ARGX ) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Beth DelGiacco - VP Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO

July 28, 2022

July 28, 2022